Comprehensive genetic analysis of the dipeptidyl peptidase-4 gene and cardiovascular disease risk factors in obese individuals

Bouchard, Luigi; Faucher, Geneviève; Tchernof, André; Deshaies, Yves; Lebel, Stéfane; Hould, Frédéric-Simon; Marceau, Picard; Vohl, Marie-Claude
March 2009
Acta Diabetologica;Mar2009, Vol. 46 Issue 1, p13
Academic Journal
The incretin system has been shown to stimulate insulin secretion in a glucose dependent manner and currently fosters considerable hope for the treatment of diabetes. Recently, we have shown that the dipeptidylpeptidase-4 ( DPP4) gene, which is responsible for incretin inactivation, was overexpressed in omental adipose tissue of obese men with the metabolic syndrome, compared to men not characterized by this condition. Since the cardiovascular disease (CVD) risk profile shows substantial inter-individual variability in obesity, this study aimed at verifying whether DPP4 polymorphisms contribute to explain such a difference. In the first step of this multi-stage study, seven tagging SNPs were genotyped in a sample of 576 obese (BMI > 40 kg/m2) individuals and tested for their association with blood pressure and lipids, as well as diabetes-related phenotypes. Then, in an additional sample of 572 obese individuals (stage 2), SNPs showing trends ( P < 0.10) for an association in the first sample were genotyped and reanalyzed. Logistic regressions were used to compute odds ratio for obesity-related metabolic complications. In sample 1, homozygotes for rs17848915 and rs7608798 minor alleles were at lower risk of hyperglycemia/diabetes ( P = 0.002) and elevated plasma triglyceride levels ( P = 0.030) respectively, whereas rs1558957 heterozygotes were at higher risk to have high plasma triglyceride ( P = 0.040), HDL- ( P = 0.021), LDL- ( P = 0.001) and total-cholesterol ( P = 0.003) levels. However, none of these associations was consistently replicated in stage 2. This first comprehensive genetic analysis does not support the notion that DPP4 polymorphisms could modulate the CVD risk profile among obese patients.


Related Articles

  • Effect of CYP2C9 gene polymorphisms on response to treatment with sulfonylureas in a cohort of Egyptian type 2 diabetes mellitus patients. Salam, Randa; Zeyada, Reham; Osman, Noha // Comparative Clinical Pathology;Mar2014, Vol. 23 Issue 2, p341 

    Oral hypoglycemics are a widely prescribed group of drugs for the management of type 2 diabetes mellitus. Sulfonylureas (SUs) are the cornerstone of type 2 diabetes pharmacotherapy. The enzyme cytochrome P450 2C9 (CYP2C9) is the main enzyme that catalyzes the biotransformation of SUs. It is...

  • Administrative Claims Analysis of New Exenatide Patients with Type 2 Diabetes. Wade, Ron; Quimbo, Ralph; Barron, John; Schroeder, Brock; Wintle, Matthew; Misurski, Derek; Oglesby, Alan // Diabetes;Jun2007 Supplement 1, Vol. 56, pA561 

    Traditional antidiabetic therapies often fail to maintain glycemic control over time. In this retrospective analysis using a large, national commercial health care claims database, we describe baseline characteristics, comorbidities, and concomitant therapies in patients prescribed exenatide in...

  • An Economic Evaluation of Primary Prevention of Cardiovascular Events in Type 2 Diabetes From Short-Term and Lifetime Perspectives. Ramsey, Scott D.; Clarke, Lauren D.; Roberts, Craig; Sullivan, Sean D.; Johnson, Scott; Liu, Larry Z. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA311 

    The article focuses on the cost-effectiveness of atorvastatin as primary prevention of cardiovascular events in Type 2 Diabetes from short-term and lifetime perspectives. Atorvastatin for persons with type 2 diabetes and normal LDL cholesterol reduced cardiovascular (CV) events based on the...

  • Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data.  // Cardiovascular Diabetology;2012, Vol. 11 Issue 1, p6 

    The article presents a research which examines the efficacy of cardiovascular (CV) safety of the selective dipeptidyl peptidase-4 (DPP-4) inhibitor saxagliptin for the treatment of type 2 diabetes mellitus (T2DM). It is reported that, the researchers carried out a retrospective meta-analysis to...

  • Challenge calls for discovery of new insulin.  // Endocrine Today;Oct2011, Vol. 9 Issue 10, p19 

    The article focuses on the 100,000 U.S. dollar challenge announced by the Juvenile Diabetes Research Foundation and InnoCentive to look for innovative ways to approach the discovery and development of a glucose-responsive insulin to treat diabetes.

  • Clinical Q & A.  // Drug Topics;11/20/2000, Vol. 114 Issue 22, p41 

    Answers a question on the difference of insulin glargine and insulin aspart from the older insulins. Characteristic of diabetes mellitus (DM); Insulin products used in the treatment of DM; Number of people in the United States affected by the disease.

  • Antihyperglycaemic use up but varied in Europe.  // PharmacoEconomics & Outcomes News;10/21/2006, Issue 514, p6 

    The article reveals that the overall use of antihyperglycaemic drugs has increased over time in Europe, but large differences in use between countries are apparent, according to a study conducted by a multinational group of researchers. In England and Germany, the use of insulin doubled over the...

  • Does Pro12Ala Polymorphism Enhance the Physiological Role of PPARγ2? Pereira, A. C.; Oliveira, R.; Castro, A. C.; Fernandes, R. // PPAR Research;2013, p1 

    Obesity and type 2 diabetes mellitus (T2D) are two major public health problems that have motivated the scientific community to investigate the high contribution of genetic factors to these disorders. The peroxisome proliferator activated by gamma 2 (PPARγ2) plays an important role in the...

  • Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patients. Umamaheswaran, Gurusamy; Praveen, Ramakrishnan; Damodaran, Solai; Das, Ashok; Adithan, Chandrasekaran // Clinical & Experimental Medicine;Nov2015, Vol. 15 Issue 4, p511 

    Metformin is an oral antidiabetic drug, commonly used for treating type 2 diabetes mellitus (T2DM) patients. It is transported into the hepatocytes by polyspecific organic cation transporter 1, which is encoded by the gene SLC22A1. It has been hypothesized that genetic variations of SLC22A1 gene...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics